 Katja Kiseljak-Vassiliades
Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenocortical Carcinoma | 14 | 2024 | 63 | 6.230 |
Why?
| | Adrenal Cortex Neoplasms | 13 | 2024 | 60 | 5.270 |
Why?
| | Adenoma | 5 | 2019 | 214 | 1.450 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.390 |
Why?
| | Cadherins | 2 | 2024 | 190 | 1.240 |
Why?
| | Pituitary Neoplasms | 8 | 2024 | 179 | 1.200 |
Why?
| | Neuroendocrine Tumors | 2 | 2024 | 99 | 0.980 |
Why?
| | Adrenal Cortex | 3 | 2020 | 27 | 0.900 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 11 | 0.900 |
Why?
| | Pituitary Gland | 4 | 2018 | 148 | 0.800 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4078 | 0.770 |
Why?
| | Dehydroepiandrosterone | 1 | 2022 | 51 | 0.760 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2024 | 1336 | 0.720 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 83 | 0.700 |
Why?
| | Androgens | 1 | 2022 | 177 | 0.700 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 627 | 0.680 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 191 | 0.680 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 131 | 0.630 |
Why?
| | Genes, Tumor Suppressor | 3 | 2017 | 87 | 0.630 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 232 | 0.620 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 33 | 0.560 |
Why?
| | Desmosomes | 1 | 2017 | 21 | 0.550 |
Why?
| | Cell Line, Tumor | 12 | 2025 | 3186 | 0.540 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.500 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2024 | 808 | 0.490 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 74 | 0.490 |
Why?
| | Acromegaly | 1 | 2014 | 13 | 0.460 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 757 | 0.450 |
Why?
| | Membrane Proteins | 2 | 2019 | 1125 | 0.450 |
Why?
| | Human Growth Hormone | 1 | 2014 | 45 | 0.440 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 168 | 0.440 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2046 | 0.420 |
Why?
| | Mitotane | 2 | 2024 | 10 | 0.410 |
Why?
| | Humans | 35 | 2025 | 129626 | 0.320 |
Why?
| | Apoptosis | 6 | 2021 | 2492 | 0.310 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 943 | 0.300 |
Why?
| | Cell Proliferation | 7 | 2023 | 2373 | 0.300 |
Why?
| | Mice, Nude | 2 | 2020 | 682 | 0.290 |
Why?
| | Genomics | 2 | 2024 | 718 | 0.290 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1164 | 0.270 |
Why?
| | Transcriptome | 3 | 2024 | 876 | 0.260 |
Why?
| | Immunotherapy | 2 | 2021 | 596 | 0.250 |
Why?
| | Prognosis | 3 | 2022 | 3774 | 0.250 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1687 | 0.250 |
Why?
| | Middle Aged | 10 | 2024 | 31136 | 0.240 |
Why?
| | Nephritis, Interstitial | 1 | 2025 | 13 | 0.240 |
Why?
| | Amino Acid Transport System y+ | 1 | 2024 | 8 | 0.230 |
Why?
| | Sulfasalazine | 1 | 2024 | 23 | 0.230 |
Why?
| | Drug Repositioning | 1 | 2024 | 26 | 0.230 |
Why?
| | Mice | 9 | 2025 | 16961 | 0.220 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2024 | 155 | 0.210 |
Why?
| | Animals | 13 | 2025 | 35391 | 0.200 |
Why?
| | Luteinizing Hormone | 1 | 2023 | 178 | 0.200 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 170 | 0.200 |
Why?
| | Anorexia | 1 | 2022 | 17 | 0.200 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 584 | 0.190 |
Why?
| | Aldosterone | 2 | 2019 | 43 | 0.180 |
Why?
| | Adult | 9 | 2024 | 35599 | 0.180 |
Why?
| | Hormone Replacement Therapy | 1 | 2022 | 93 | 0.180 |
Why?
| | Female | 11 | 2025 | 68734 | 0.180 |
Why?
| | Aurora Kinase A | 1 | 2021 | 54 | 0.180 |
Why?
| | Phthalazines | 1 | 2021 | 41 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 133 | 0.170 |
Why?
| | Pheochromocytoma | 1 | 2021 | 57 | 0.170 |
Why?
| | Adrenal Gland Diseases | 1 | 2020 | 6 | 0.170 |
Why?
| | Paraganglioma | 1 | 2021 | 49 | 0.170 |
Why?
| | Benzamides | 1 | 2021 | 203 | 0.170 |
Why?
| | Indolizines | 1 | 2019 | 4 | 0.160 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 7 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 175 | 0.160 |
Why?
| | Estrogens | 1 | 2022 | 347 | 0.160 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 201 | 0.160 |
Why?
| | Quinoxalines | 1 | 2019 | 64 | 0.160 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 95 | 0.160 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2018 | 10 | 0.150 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 132 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 170 | 0.150 |
Why?
| | Gadolinium | 1 | 2019 | 78 | 0.150 |
Why?
| | Lamin Type B | 1 | 2018 | 7 | 0.150 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 8 | 0.150 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.150 |
Why?
| | Trans-Activators | 1 | 2021 | 393 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2024 | 14522 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2023 | 639 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 887 | 0.140 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 213 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 326 | 0.140 |
Why?
| | Signal Transduction | 4 | 2023 | 4931 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2019 | 213 | 0.140 |
Why?
| | Immunoblotting | 1 | 2018 | 305 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 204 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 181 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 329 | 0.140 |
Why?
| | Kidney | 1 | 2025 | 1386 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 591 | 0.140 |
Why?
| | Mutation | 3 | 2021 | 3717 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 142 | 0.140 |
Why?
| | Microarray Analysis | 1 | 2017 | 116 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1250 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1685 | 0.130 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 14 | 0.130 |
Why?
| | Contrast Media | 1 | 2019 | 393 | 0.130 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 74 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 749 | 0.120 |
Why?
| | Gonadotrophs | 2 | 2015 | 21 | 0.120 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 145 | 0.120 |
Why?
| | Aged | 5 | 2024 | 22061 | 0.120 |
Why?
| | Phosphorylation | 1 | 2019 | 1713 | 0.120 |
Why?
| | Testosterone | 2 | 2023 | 372 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 636 | 0.110 |
Why?
| | Male | 9 | 2024 | 63670 | 0.110 |
Why?
| | Cell Survival | 4 | 2021 | 1076 | 0.100 |
Why?
| | Prospective Studies | 2 | 2023 | 7135 | 0.100 |
Why?
| | Veterans | 1 | 2023 | 1375 | 0.090 |
Why?
| | Hypogonadism | 1 | 2012 | 84 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 82 | 0.090 |
Why?
| | Models, Molecular | 1 | 2015 | 1491 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2688 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 481 | 0.090 |
Why?
| | Young Adult | 2 | 2024 | 12455 | 0.080 |
Why?
| | Glycoproteins | 1 | 2012 | 338 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 314 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2010 | 205 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 404 | 0.080 |
Why?
| | Reproduction | 1 | 2010 | 199 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 478 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1282 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2016 | 1167 | 0.070 |
Why?
| | Models, Biological | 2 | 2012 | 1724 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3394 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3152 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 756 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2455 | 0.060 |
Why?
| | Carcinoma, Papillary | 1 | 2006 | 77 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 157 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1613 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 948 | 0.060 |
Why?
| | Gene Silencing | 1 | 2006 | 190 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2326 | 0.060 |
Why?
| | Up-Regulation | 2 | 2021 | 840 | 0.060 |
Why?
| | Ipilimumab | 1 | 2025 | 31 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2006 | 210 | 0.060 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 87 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 1928 | 0.060 |
Why?
| | United States | 1 | 2020 | 13871 | 0.050 |
Why?
| | Floxuridine | 1 | 2023 | 5 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1049 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 27 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2023 | 59 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2024 | 230 | 0.050 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 312 | 0.050 |
Why?
| | Stress, Physiological | 2 | 2015 | 414 | 0.050 |
Why?
| | RNA, Long Noncoding | 1 | 2024 | 179 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2023 | 237 | 0.050 |
Why?
| | Neurons | 1 | 2010 | 1494 | 0.050 |
Why?
| | DNA Methylation | 1 | 2006 | 611 | 0.050 |
Why?
| | Cellular Senescence | 1 | 2023 | 181 | 0.050 |
Why?
| | Aurora Kinase B | 1 | 2021 | 8 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 67 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 84 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 387 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 350 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 370 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 524 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 587 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 460 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 151 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 427 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 354 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1592 | 0.040 |
Why?
| | MicroRNAs | 1 | 2024 | 679 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 274 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 330 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 958 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2784 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 109 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 141 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 32 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 56 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 355 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 100 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 104 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2881 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 168 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 234 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 276 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 274 | 0.030 |
Why?
| | Aging | 1 | 2023 | 1778 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2016 | 672 | 0.030 |
Why?
| | Indoles | 1 | 2015 | 383 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 432 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3075 | 0.020 |
Why?
| | Binding Sites | 1 | 2015 | 1248 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 843 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 36 | 0.020 |
Why?
| | Athletes | 1 | 2016 | 411 | 0.020 |
Why?
| | Sulfonamides | 1 | 2015 | 497 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 113 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 152 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 269 | 0.020 |
Why?
| | Genes, p53 | 1 | 2011 | 70 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 796 | 0.020 |
Why?
| | Olfactory Pathways | 1 | 2010 | 60 | 0.020 |
Why?
| | Protein Binding | 1 | 2015 | 2124 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 611 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1035 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 384 | 0.020 |
Why?
| | Neurogenesis | 1 | 2010 | 126 | 0.020 |
Why?
| | Hypoxia | 1 | 2015 | 1084 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1207 | 0.020 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2006 | 21 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 8 | 0.020 |
Why?
| | Death-Associated Protein Kinases | 1 | 2006 | 11 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2006 | 51 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5415 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 181 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 2100 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 182 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2006 | 131 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 949 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 10219 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2442 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7052 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 20412 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2627 | 0.010 |
Why?
|
|
Kiseljak-Vassiliades's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|